{
    "relation": [
        [
            "",
            "Cohort I (DTG 50 mg OD)",
            "Cohort II (DTG 50 mg BID)"
        ],
        [
            "Description",
            "Participants received dolutegravir (DTG) 50 milligrams (mg) once a day (OD).",
            "Participants received DTG 50 mg twice a day (BID)."
        ]
    ],
    "pageTitle": "A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00950859?sect=Xl015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438043060830.93/warc/CC-MAIN-20150728002420-00322-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 863857204,
    "recordOffset": 863841577,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Participants recruited initially to Cohort I and subsequently to Cohort II. Recruitment to Cohort I was closed 9 months before recruitment to Cohort II was opened. Recruitment was not randomized. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: GSK1349572 (Cohort I) Drug: GSK1349572 (Cohort II) Interventions: Infection, Human Immunodeficiency Virus Condition: Allocation:\u00a0Non-Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Single\u00a0Group\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Cohort I (DTG 50 mg OD) \u00a0 \u00a0 Cohort II (DTG 50 mg BID) \u00a0 STARTED \u00a0 \u00a0 27 \u00a0 \u00a0 24 \u00a0 Ongoing \u00a0 \u00a0 13 \u00a0 \u00a0 19 \u00a0 COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 NOT COMPLETED \u00a0 \u00a0 27 \u00a0 \u00a0 24 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 Insufficient Viral Load Response \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 12 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}